Monoclonal antibody therapies for COVID-19: lessons learned and implications for the development of future products()

Several companies were authorized to treat COVID-19 patients with monoclonal antibodies within 1–2 years of the start of the pandemic. These products were discovered, developed, manufactured, clinically tested, and approved under emergency-use authorization at unprecedented speed. Pandemic urgency l...

Descripción completa

Detalles Bibliográficos
Autores principales: Kelley, Brian, De Moor, Pam, Douglas, Kristen, Renshaw, Todd, Traviglia, Stacey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436891/
https://www.ncbi.nlm.nih.gov/pubmed/36179406
http://dx.doi.org/10.1016/j.copbio.2022.102798

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436891/
https://www.ncbi.nlm.nih.gov/pubmed/36179406
http://dx.doi.org/10.1016/j.copbio.2022.102798

Ejemplares similares